Mass balance study of [ 14C]eribulin in patients with advanced solid tumors

Drug Metabolism and Disposition

Volumn 40, Issue 2, 2012, Pages 313-321

  Dubbelman, Anne Charlotte ^a,b   Rosing, Hilde ^b   Jansen, Robert S ^b   Mergui Roelvink, Marja ^a   Huitema, Alwin D R ^b   Koetz, Barbara ^c   Lymboura, Margarita ^c   Reyderman, Larisa ^d   Lopez Anaya, Arturo ^e   Schellens, Jan H M ^a,f   Beijnen, Jos H ^b,f  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c EISAI CO LTD   (Japan)

^d EISAI INC   (United States)

^e Forest Laboratories Inc   (United States)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ERIBULIN; ERIBULIN C 14; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; ESOPHAGUS TUMOR; FATIGUE; FECES; FEMALE; HUMAN; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; LIQUID SCINTILLATION COUNTING; LUNG TUMOR; MALE; MASS BALANCE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; METABOLIC PARAMETERS; MULTIPLE CYCLE TREATMENT; NASOPHARYNX TUMOR; OVARY TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE TUMOR; RADIOACTIVITY; RADIOCHROMATOGRAPHY; SOLID TUMOR; TANDEM MASS SPECTROMETRY; TESTIS TUMOR; URINARY EXCRETION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CARBON RADIOISOTOPES; FECES; FEMALE; FURANS; HALF-LIFE; HUMANS; KETONES; MALE; METABOLIC CLEARANCE RATE; MICROTUBULES; MIDDLE AGED; NEOPLASMS; TUBULIN MODULATORS;

EID: 84856013638     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.042762     Document Type: Article

References (21)

1. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, and Hamel E (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266:15882-15889. (Pubitemid 21907740)
2. Beumer JH, Beijnen JH, and Schellens JH (2006) Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet 45:33-58. (Pubitemid 43145014)
3. Cigler T and Vahdat LT (2010) Eribulin mesylate for the treatment of breast cancer. Expert Opin Pharmacother 11:1587-1593.
4. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, et al. (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914-923.
5. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, et al. (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28:3922-3928.
6. Currie LA (1968) Limits for qualitative detection and quantitative determination. Application to radiochemistry. Anal Chem 40:586-593.
7. Devriese LA, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, and Schellens JH (2011a) Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. EJC Supplements 8:181.
8. Devriese LA, Witteveen P, Voest EE, Overkleeft EN, Langenberg M, Beijnen JH, Reyderman L, Wanders J, Mould DR, Gupta A, et al. (2011b) Eribulin dosing in patients with advanced solid tumors and hepatic impairment. J Clin Oncol 29 (Suppl):2544.
9. Dubbelman AC, Rosing H, Thijssen B, Lucas L, Copalu W, Wanders J, Schellens JH, and Beijnen JH (2011) Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci 879:1149-1155.
10. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, et al. (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15:4207-4212.
11. Hirata Y and Uemura D (1986) Halichondrins - antitumor polyether macrolides from a marine sponge. Pure Appl Chem 58:701-710. (Pubitemid 16557441)
12. Jackson KL, Henderson JA, and Phillips AJ (2009) The halichondrins and E7389. Chem Rev 109:3044-3079.
13. Reyderman L, Gupta A, Pelletier RD, and Wong N (2011) Eribulin and cytochrome P450 effectors: in vitro studies and population pharmacokinetic- pharmacodynamic analysis. EJC Supplements 8:181.
14. Synold TW, Tsao-Wei DD, Quinn DI, Groshen SG, Aparicio A, Twardowski P, Stadler WM, Gandara DR, Lara P Jr, and Newman EM (2010) Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): A California Cancer Consortium Trial. J Clin Oncol 28 (Suppl):2527.
15. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, Ashworth S, and Rosen LS (2009) Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 15:4213-4219.
16. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, et al. (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013-1021. (Pubitemid 32174419)
17. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, et al. (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954-2961.
18. Vahdat LT, Twelves C, Allison MK, Cortes JA, Campone M, Shuster DE, Wanders J, Fang F, Gurnani RD, and Blum JL (2008) Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy. J Clin Oncol 26 (Suppl):1084.
19. van den Bongard HJ, Pluim D, Rosing H, Nan-Offeringa L, Schot M, Ravic M, Schellens JH, and Beijnen JH (2002) An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anticancer Drugs 13:807-814.
20. Zhang ZY, King BM, Pelletier RD, and Wong YN (2008) Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol 62:707-716.
21. Zhu M, Zhao W, Vazquez N, and Mitroka JG (2005) Analysis of low level radioactive metabolites in biological fluids using high-performance liquid chromatography with microplate scintillation counting: method validation and application. J Pharm Biomed Anal 39:233-245. (Pubitemid 41112142)